SHAREHOLDER ALERT: The M&A Class Action Firm Investigates the Merger of Inozyme Pharma, Inc. - INZY

Group 1 - Monteverde & Associates PC is investigating Inozyme Pharma, Inc. regarding its proposed merger with BioMarin Pharmaceutical Inc. [1] - BioMarin will initiate a cash tender offer to acquire all outstanding shares of Inozyme common stock at a price of $4.00 per share [1] - Monteverde & Associates PC has a successful track record in recovering millions of dollars for shareholders and is recognized as a Top 50 Firm in the 2024 ISS Securities Class Action Services Report [1] Group 2 - The firm is headquartered in the Empire State Building, New York City [1] - Monteverde & Associates PC is a national class action securities firm with experience in trial and appellate courts, including the U.S. Supreme Court [2] - The firm encourages shareholders with concerns to contact them for additional information free of charge [3]